Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE 3 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus SODIUM CHLORIDE 3 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Hypertonic sodium chloride solution (3%) increases extracellular osmolarity, drawing water from intracellular space into extracellular compartment via osmotic gradient, thereby reducing cerebral edema and intracranial pressure. Sodium ions also restore electrolyte balance in hyponatremia.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion of 3% sodium chloride at a rate of 1-2 mL/kg/hour, with a typical rate of 50-100 mL/hour for adults, titrated to serum sodium goals. Maximum infusion rate: 100 mL/hour, with careful monitoring of serum sodium (increase not >8-10 mEq/L per 24 hours).
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable: sodium and chloride are endogenous electrolytes; administered dose mixes with body pools and is eliminated via renal excretion with a half-life dependent on renal function and hydration status. In euvolemic individuals with normal renal function, the terminal elimination half-life of excess sodium is approximately 6–12 hours.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal (essentially 100%): sodium and chloride ions are excreted unchanged in urine. No biliary or fecal elimination of intact drug; sodium and chloride are obligately filtered and variably reabsorbed based on volume status and renal function.
Category C
Category A/B
Electrolyte
Electrolyte